Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 1, 2008

Dr. Reddy’s Picks Up Part of Dowpharma’s Small Molecule Franchise Based in U.K.

  • Dr. Reddy’s plans to purchase a segment of Dowpharma’s small molecule business. Dr. Reddy’s also gains a nonexclusive license to Dow’s Pfenex Expression Technology™ for biocatalysis development. The agreements will give Dr. Reddy’s expanded capabilities to provide custom pharmaceutical services.

    The acquisition includes facilities in Mirfield and Cambridge, which are both in the U.K. “The proprietary chiral and biocatalysis technology at the Cambridge site and the scale-up capability in the Mirfield site will add significant value to the company,” points out Satish Reddy, managing director and COO. “This acquisition will also bring strengths in industrial synthesis of complex prostaglandins and carbohydrate chemistry.”

    The transaction is scheduled to close on April 30. Dr. Reddy’s will gain business, customer contracts, associated products, process technology, intellectual property, trademarks, and the transfer of the U.K. centers.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »